Yu (Ray) Zuo, MD, MS

portrait of Yu Zuo
Edward T and Ellen K Dryer Early Career Professor of Rheumatology
Assistant Professor of Internal Medicine and Antiphospholipid Syndrome Program Associate Director
Internal Medicine
Medical School
[email protected]
Available to mentor
Yu (Ray) Zuo, MD, MS
portrait of Yu Zuo
Assistant Professor
  • About
  • Qualifications
  • Center Memberships
  • Recent Publications
  • Manage Your Profile

  • About

    Dr. Zuo is the Edward T. and Ellen K. Dryer Early Career Professor of Rheumatology, Assistant Professor in the Department of Internal Medicine, and the Antiphospholipid Syndrome Program associate director at the University of Michigan. His research focuses on the pathogenic role of neutrophil extracellular traps (NETs) and autoimmunities against NETs in various thromboinflammatory diseases such as antiphospholipid syndrome (APS), vasculitis and COVID-19. He has authored more than 50 papers, and his current research is supported by the National Institute of Health, Taubman Medical Research Institute, Arthritis National Research Foundation, the National Institute of Health, the Rheumatology Research Foundation, and the Frankel Cardiovascular Center at the University of Michigan support his current research. He has earned the distinction of being named a Taubman Institute Emerging Scholar and was also the recipient of the 2024 American Society of Clinical Investigation Young Physician-Scientist Award.

    Qualifications

    • MS
      UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, Texas, 75390, United States
      2016 - 2018
    • MD
      Ross University School of Medicine, 2300 SW 145th Avenue, Miramar, FL, 33027, United States
      2007 - 2011

    Center Memberships

    • Center Member
      Taubman Institute
    • Center Member
      Samuel and Jean Frankel Cardiovascular Center

    Recent Publications

    See All Publications
    • Journal Article
      Endothelial cell-derived plasminogen activator inhibitor-1 potentiates thrombosis in antiphospholipid syndrome
      Gan Y, Liang W, Liu C, Yalavarthi S, Warnock M, Sabb K, Sarosh C, Schaefer JK, Tambralli A, Madison JA, Emal CD, Tsou PS, Shi H, Zuo Y, Lawrence DA, Knight JS. Journal of Autoimmunity, 2026 Jun 1; 161: DOI:10.1016/j.jaut.2026.103563
    • Proceeding / Abstract / Poster
      The Association of Calprotectin with Vascular Injury and Remodeling in Clinically-Isolated Aortitis
      Kmetova K, Zuo, MD, MS YR, Gewurz-Singer O. 2026 Feb 23;
    • Journal Article
      Prothrombotic Activation of Platelet Pannexin 1 Channels in Antiphospholipid Syndrome.
      Mazetto Fonseca BDM, NaveenKumar SK, Yalavarthi S, Sugur K, Newman TG, Hoy CK, Sarosh C, Schaefer JK, Tambralli A, Madison JA, Zuo Y, Orsi F, Holinstat M, Knight JS. Arthritis Rheumatol, 2025 Dec 1; DOI:10.1002/art.70001
      PMID: 41327823
    • Proceeding / Abstract / Poster
      Aspirin use among patients with thrombotic antiphospholipid antibody syndrome
      King S, Sarosh C, Tambralli A, Madison J, Zuo Y, Sood S, Girard J, Shevell L, Knight J, Schaefer J. Blood, 2025 Dec 8; 146 (Supplement 1): 3109 DOI:10.1182/blood-2025-3109
    • Proceeding / Abstract / Poster
      A New Link Between Calprotectin, Cholesterol Efflux Dysfunction, and Premature Atherosclerosis in Juvenile Dermatomyositis
      Chong E, Sugur K, Matossian S, Kmetova K, Christine G, Turnier J, Zuo, MD, MS Y. 2025 Oct 28;
    • Proceeding / Abstract / Poster
      Performance of the 2023 and 2006 APS Classification Criteria in Pediatric Patients Diagnosed with APS: A Multisite Cohort Study
      Madison J, Sloan E, Kwan O, Saez C, Lewis K, Marilao J, Baay B, Elrefai R, Dale M, McCurdy D, Goteti S, Bhatt J, Ogbu E, Knight J, Zuo, MD, MS Y. 2025 Oct 9;
    • Proceeding / Abstract / Poster
      The Association of Calprotectin with Vascular Injury and Remodeling in Clinically-Isolated Aortitis
      Kmetova K, Poppey G, Sugur K, Ford J, Liang W, Merkel P, Chong E, Yalavarthi S, NaveenKumar S, Milman N, Gewurz-Singer O, Zuo, MD, MS YR. 2025 Oct 5;
    • Journal Article
      A Disrupted Adenosinergic Axis Facilitates Platelet Activation in APS: Exploring a Novel Therapeutic Target.
      NaveenKumar SK, Newman TG, Fonseca BM, Yalavarthi S, Flores Nascimento MC, Sabb K, Kmetova K, Chong E, Sugur K, Ranger CH, Tompkins MP, Sarosh C, Madison JA, Tambralli A, Schaefer JK, Holinstat M, Zuo Y, Knight JS. Blood Adv, 2025 Jul 24; DOI:10.1182/bloodadvances.2025016162
      PMID: 40705954

    Featured News & Stories

    Department News

    What Is Antiphospholipid Syndrome (APS) “Brain Fog”? If I Have APS “Brain Fog,” What Can I Do To Help?

    In this edition of the APS Program Community Q&A Series, Dr. Ray Zuo discusses what APS "brain fog" is, and what you can do to help.
    blood vials and person putting gauze pad on arm
    Health Lab

    Using gene expression in blood to personalize care for APS

    Antiphospholipid syndrome looks different in every patient. By using whole-blood RNA sequencing and machine learning, University of Michigan Health researchers reveal distinct immune patterns that may pave the way for personalized treatment.
    travel
    Department News

    What can I do to prepare for my holiday trip?

    In this month’s edition, Dr. Zuo provides some updates to a previous topic regarding travel!
    CAR-T Cell Therapy
    Department News

    CAR-T Cell Therapy: What It Is and How It Could Help APS Patients in the Future

    In this edition of the APS Program Community Q&A Series, Dr. Ray Zuo and Dr. Maximilian Konig explore CAR-T Cell Therapy, what it is, and how it could help APS patients.
    Mark Hall
    Department News

    Inside APS: A Patient's Personal Health Journey

    In 1994, Mark Hall was diagnosed with antiphospholipid syndrome (APS).
    two hearts next to each other with small figure people inside and out of it
    Health Lab

    How neutrophil calprotectin unmasks future atherosclerotic heart disease risk

    The immune system is showing evidence of playing a roll in the emergence of atherosclerotic cardiovascular disease. A rush of neutrophils, or immune cells to the site could be an explanation for how this condition forms as well as how to prevent this heart disease in the future.